Minerva Neurosciences starts Phase 3 trial for roluperidone to treat negative schizophrenia symptoms

Minerva Neurosciences has initiated a global Phase 3 clinical trial for roluperidone, targeting negative symptoms of schizophrenia, with topline data expected in the second half of 2027. This trial follows positive results from earlier phases and aims to address a significant unmet medical need, as no approved treatments currently exist for these symptoms. The study will enroll about 380 patients worldwide and also assess long-term relapse rates compared to common antipsychotics. Minerva reported increased R&D and administrative expenses in Q1 2026 and holds $78.2 million in cash, positioning it to advance this critical program.